Manchester Fungal Infection Group

Understanding and reducing the burden of human fungal diseases.


The Manchester Fungal Infection Group (MFIG) is an established international centre of excellence for fungal infection biology and translational antifungal research at The University of Manchester.

Fungal diseases kill more people annually than tuberculosis or malaria, but are very poorly understood.

Resistance to frontline antifungal agents is a growing public health concern due to extensive fungicide use in agriculture, and fungal infections are thought to contribute significantly to morbidity in influenza and COVID-19.

“Fungal diseases kill more people annually than tuberculosis or malaria…”

Manchester hosts the largest centre in the world for research into and treatment of fungal respiratory and mucosal diseases, with more than 70 university and NHS staff and students, including 10 academics/clinician academics.

MFIG is the academic research arm of this group and works alongside the National Aspergillosis Centre, headed by Dr Chris Kosmidis, and the Mycology Reference Laboratory, headed by Dr Riina Richardson. Our combined aim is to understand and reduce the burden of human fungal diseases.


Major research activites

Our research builds on a series of high-profile publications and outputs from ongoing projects funded by the MRC, BBSRC, Wellcome Trust and NIH, among others.

Using the human pathogen Aspergillus fumigatus as our main experimental system, MFIG’s research is focused on five integrated themes.

Host-pathogen interactions

Our understanding of how fungi invade, regulate and interact with the cells, tissues and systems of the host immune system is limited.

Our research in this area is broad, and projects are investigating epithelial cell and immune cell interaction with fungi in vitro, as well as with in vivo models within murine or invertebrate hosts and human corneal models of the eye.

Considerable emphasis is being placed on live-cell imaging and the development of high throughput live-cell screens in these studies.


Dr Margherita Bertuzzi

Principal investigators:

Genetics and genomics

All humans inhale hundreds of A. fumigatus spores each day, but only a few will develop symptoms of fungal disease.

Our understanding of the factors that affect susceptibility to aspergillosis and to other fungal diseases is limited. Our research aims to shed light on the genetic aspect of human susceptibility, in order to aid identification of at-risk groups and to help identify host pathways that may benefit from targeted supplementation.


Prof Paul Bowyer

Principal investigators:

Novel target development and drug discovery

Many of the current antifungal treatments for chronic fungal infections have multiple distressing side effects.

There are also few antifungals available to treat invasive fungal diseases, and the last antifungal target for a commercially available antifungal drug was discovered in 1974, with the antifungal being licensed in 2006.

These facts mean that the need for novel antifungals is as strong as ever. We aim to discover new antifungal drugs with novel modes of action using high throughput screening and advanced live-cell imaging techniques.


Prof Mike Bromley

Principal investigators:

Antifungal resistance

Resistance to antifungals (especially azoles) is rapidly increasing. Our research aims to investigate specific resistance mechanisms and how to combat these.

In Manchester, we have identified a series of target (cyp51A) and non-target (transporters, transcription factors, phosphoregulators and genes involved in mitochondrial function) mechanisms that control resistance to the azole class of antifungals.

We have employed this knowledge to develop a series of diagnostics to detect resistance in the clinic.

We are currently leading a multi-centre project to generate a genome-wide knockout collection in A. fumigatus to identify further mechanisms of drug resistance and pathogenicity.


Prof Mike Bromley

Principal investigators:

Co-infections in fungal disease

Association between microorganisms is part of an evolutionary strategy to colonise and cause disease in humans.

As clinical evidence for the common occurrence of combined infection by fungi and other microorganisms increases, research into the mechanism and consequences of their interaction is becoming more relevant.

Projects in this area are focused on investigating the mechanistic by which viral or bacterial infections contribute to an impaired anti-fungal potency of the epithelium, and the impact of these interactions in the outcome of diseases.”


Dr Sara Gago

Principal investigators:

Research publications

View selected publications below, or see a full list in the University Research Explorer.

Highlight publications


Key people

Professor Mike Bromley

Director, Manchester Fungal infection Group

Read Mike’s research profile

Professor David Denning

Professor of Infectious Diseases in Global Health

Read David’s research profile


Professor Paul Bowyer

Professor in Molecular Biology

Read Paul’s research profile

Professor Malcolm Richardson

Honorary Professor of Medical Mycology and Consultant Clinical Scientist in Medical Mycology, Mycology Reference Centre

Read Malcolm’s research profile


Dr Riina Richardson

Clinical Senior Lecturer and Consultant for the Manchester University NHS Foundation Trust (MFT)

Read Riina’s research profile

Dr Margherita Bertuzzi

Lecturer in Molecular Microbiology

Read Margherita’s research profile


Key activities

MFIG is part of the wider Manchester Fungal Diseases Group. This means that we work closely with the National Aspergillosis Centre and the Mycology Reference Centre. We also work collaboratively with a number of research groups around the world.

In addition, we pride ourselves on our collaborations with industrial partners.

These take many forms and include:

  • research collaborations
  • sponsorship of CASE studentships
  • licensing partnerships
  • contract research for companies.

Our partners include:

  • Pfizer
  • Du Pont
  • Blueberry Therapeutics
  • F2G
  • Syngenta
  • Pharmacelsus
  • PiQ Laboratories
  • Gilead
  • Synlab
  • Syngenics
  • Pulmocide

For more information about partnerships, please contact Dr Mike Bromley by emailing


International impact

Members of MFIG are involved in several worldwide initiatives to promote education and raise awareness about fungal diseases.

Global Action for Fungal Infections (GAFFI)

GAFFI aims to improve the outcomes from fungal disease globally.

Its goals are to measure the impact of serious fungal disease and support universal access to WHO-listed essential diagnostics and antifungal treatments, through education of healthcare professionals.

GAFFI’s pioneering work in Guatemala has led to an immediate fall in deaths from AIDS. Additional country programmes and the mobilisation and empowerment of GAFFI Ambassadors though advocacy training, research support and networking will see major improvements in many countries.

Leading International Fungal Education (LIFE)

The LIFE programme provides an online educational service for healthcare professionals in English and Spanish, as well as a news service for notable advances in the field. It aims to facilitate high quality diagnostics and patient care for fungal infections everywhere.

The website provides an easily read summary of the most important fungal diseases and the top pathogens, diagnostic tests and therapies, as well as an online microscopy/histology course developed in Manchester.

The Ensembl Fungi resource

MFIG has contributed genomic data for eight different Aspergillus species and two strains for A. fumigatus to Ensembl Fungi ( This data has been collated as a central resource to support the Aspergillus research community.

This work arose from the initial sequencing projects for Aspergillus fumigatus, of which members of MFIG were heavily involved.

The Aspergillus Website
The Aspergillus Website is a worldwide comprehensive resource providing detailed information about the fungus Aspergillus and the diseases it can cause.

It provides an encyclopaedia of Aspergillus for doctors, scientists, patients and their relatives.

COFUN - Genome-wide knock out project

COFUN is a Wellcome Trust-funded project that aims to generate knockout mutants for all of the coding genes in the human pathogen Aspergillus fumigatus. In total, around 10,000 strains will be generated.

For more information about our international links and impact, please contact Prof David Denning by emailing


Training future scientists and clinicians

It is important for us to inspire, promote and support the next generation of researchers in medical mycology. We are committed to this at all levels of study, and our PIs, staff and postdoctoral researchers teach on numerous courses.

Related master’s courses

We provide training and support for MSc, MRes and MSci students from various master’s courses doing research projects. These include:

Doctoral training and postgraduate research

Within the group, we currently have around 12 PhD students and 5 postdoctoral researchers, drawn from all over the world.

We enable students to undertake a research project that will further improve their understanding of medical mycology. We also provide a framework of postgraduate research training in research council-funded doctoral training partnerships.

These include:

Visit the Faculty of Biology, Medicine and Health website to learn more about funded PhD programmes and see all PhD programmes.

For more information about teaching and learning within the group, please contact Dr Margherita Bertuzzi by emailing


Contact us

Prof Mike Bromley (Centre Director)


Follow us on X: @MFIG